AN2 Therapeutics (ANTX) Income towards Parent Company (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Income towards Parent Company data on file, last reported at -$17.3 million in Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 55.71% year-over-year to -$17.3 million in Q1 2026; TTM through Mar 2026 was -$42.6 million, a 59.35% increase from a year earlier, with the FY2025 full-year figure at -$35.3 million, up 67.7% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$17.3 million, down from -$8.9 million in the prior quarter.
• Over the last five years, Income towards Parent Company for ANTX reached as high as -$6.6 million in Q2 2025 and fell as low as -$65.6 million in Q4 2024.
• Historically, Income towards Parent Company has averaged -$22.7 million across 5 years, with a median of -$17.3 million in 2026.
• Across the five-year window, Income towards Parent Company tumbled 991.8% in 2022 and surged 86.47% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$11.9 million in 2022, then plunged by 410.98% to -$60.6 million in 2023, then slipped by 8.24% to -$65.6 million in 2024, then jumped by 86.47% to -$8.9 million in 2025, then tumbled by 95.35% to -$17.3 million in 2026.
• Per Business Quant data, the three most recent Income towards Parent Company figures were -$17.3 million in Q1 2026, -$8.9 million in Q4 2025, and -$9.7 million in Q3 2025.